Vaxxinity, Inc. (VAXX)
VAXX Stock Price Chart
Explore Vaxxinity, Inc. interactive price chart. Choose custom timeframes to analyze VAXX price movements and trends.
VAXX Company Profile
Discover essential business fundamentals and corporate details for Vaxxinity, Inc. (VAXX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
11 Nov 2021
Employees
57.00
Website
https://www.vaxxinity.comCEO
Mei Mei Hu
Description
Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology and coronaviruses in the United States. The company engages in developing UB-311 that targets toxic forms of aggregated amyloid-b in the brain to fight Alzheimer's disease (AD) that is in phase 2 clinical trial; UB-312 that targets toxic forms of aggregated a-synuclein in the brain to fight Parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy that is in phase 1 clinical trial; and an anti-tau product candidate for various neurodegenerative conditions, including AD. It is also developing UB-313 that targets calcitonin gene-related peptide to fight migraines; anti-PCSK9 that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; and UB-612 for neutralizing the SARS-CoV-2 virus, which is in phase 3 clinical trial. Vaxxinity, Inc. was founded in 2014 and is headquartered in Dallas, Texas.
VAXX Financial Timeline
Browse a chronological timeline of Vaxxinity, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Earnings released on 5 Jun 2025
Earnings released on 27 Mar 2025
Earnings released on 18 Nov 2024
Earnings released on 30 Sept 2024
Earnings released on 14 May 2024
EPS came in at -$0.15 falling short of the estimated -$0.10 by -50.00%.
Earnings released on 27 Mar 2024
EPS came in at -$0.09 surpassing the estimated -$0.13 by +30.77%.
Earnings released on 8 Nov 2023
EPS came in at -$0.10 surpassing the estimated -$0.14 by +28.57%.
Earnings released on 9 Aug 2023
EPS came in at -$0.11 surpassing the estimated -$0.16 by +31.25%.
Earnings released on 9 May 2023
EPS came in at -$0.15 surpassing the estimated -$0.16 by +6.25%.
Earnings released on 27 Mar 2023
EPS came in at -$0.16 matching the estimated -$0.16.
Earnings released on 10 Nov 2022
EPS came in at -$0.15 surpassing the estimated -$0.16 by +6.25%.
Earnings released on 11 Aug 2022
EPS came in at -$0.14 surpassing the estimated -$0.38 by +63.16%.
Earnings released on 9 May 2022
EPS came in at -$0.31 surpassing the estimated -$0.34 by +8.82%.
Earnings released on 24 Mar 2022
EPS came in at -$0.48 falling short of the estimated -$0.35 by -37.14%, while revenue for the quarter reached -$1.00K .
Earnings released on 23 Dec 2021
EPS came in at -$0.24 falling short of the estimated -$0.13 by -84.62%, while revenue for the quarter reached $50.00K .
Earnings released on 12 Nov 2021
EPS came in at -$0.22 .
Earnings released on 31 Mar 2021
EPS came in at -$0.26 , while revenue for the quarter reached $17.00K .
Earnings released on 31 Dec 2020
EPS came in at -$0.10 .
Earnings released on 30 Sept 2020
EPS came in at -$0.13 , while revenue for the quarter reached $117.00K .
VAXX Stock Performance
Access detailed VAXX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.